Valentin Garcia Gutiérrez, MD, PhD, Hospital Universitario Ramón y Cajal, Madrid, Spain, highlights the importance of developing novel treatment strategies for patients with chronic myeloid leukemia (CML) who experience life-threatening toxicities associated with the use of tyrosine kinase inhibitors (TKIs), as well as for patients who become resistant to TKIs, and to improve the quality of life (QoL) of patients who receive lifelong TKI therapy. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding, speaking engagements, ad boards: Novartis, BMS, Incyte, Pfizer